Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
about
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphomaBreaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer TherapyValidation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximabIdentification and characterization of a bacterial hyaluronidase and its production in recombinant formHYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer ResponseSubcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German CentersSubcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeysInfusion pressure and pain during microneedle injection into skin of human subjects.Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeuticsRecombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.Subcutaneous fluid administration: a potentially useful tool in prehospital careMinipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.Mechanistic determinants of biotherapeutics absorption following SC administration.Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidasePharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Subcutaneous immunoglobulin: opportunities and outlook.Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.PH20 is not expressed in murine CNS and oligodendrocyte precursor cells.Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management.Modern management of primary B-cell immunodeficiencies.Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.Therapeutic targeting of hyaluronan in the tumor stroma.Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens?Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Rituximab by subcutaneous route.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Drug Development of Therapeutic Monoclonal Antibodies.Emerging hydrogel designs for controlled protein delivery.Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
P2860
Q26775837-31F38F27-F0A8-4A86-AA9E-A9A812E80A41Q26784055-78E62146-95EE-4957-936C-D84BB7B32457Q27336141-2CBC3CA2-266B-4D30-959C-8602125A595AQ27711232-51B7B3D5-337B-4D72-BC9E-B324E2492849Q28079276-96B4DF57-C7E2-4DC2-9BC4-62E0588ECC00Q28083633-C9CF0452-14E8-43B1-8A7C-AE2973065C89Q28535043-4C17214A-FA75-41BC-BA0B-7A42CA577614Q30462818-F5377C01-9FD7-48E7-9129-6B16154D1A03Q35032702-0DE40CDA-EAEC-4BF2-B9AB-D2D116CE241FQ35580799-5D3EF737-578B-4D07-B643-796F18E342A8Q35914396-F460243C-612B-4025-BFC6-E280D8C96720Q35967897-A4BD00D9-0B37-4528-BE07-745678755756Q35977557-7D779C66-601D-4ADB-8F16-23184DD0EC70Q35992509-0D205017-10F9-4E4B-8EA9-1A029AA140E0Q36065572-85C7AC16-8EB6-4589-98E6-632BEF7D06EDQ36229271-B72AFCAA-094A-4095-BB58-D074E29F9469Q36243612-98C73564-4B6E-483F-8D76-83E6E6FDFDE2Q36360553-FF4517E9-AC9D-4432-9452-469E9A055A93Q36560273-8A92D981-66ED-42D6-8CD3-2D64F8DC03ABQ36617983-A38FC698-D008-49F1-A4EF-F81F1EC6C610Q37083973-FA08796A-0433-4FB8-B83C-9336956971FBQ37626132-3DE89B65-798B-4256-85DA-B53C397F5147Q37672846-23672DF6-D649-4A54-B0C2-39D2AD5E70A1Q37682029-FB7F76A1-DF40-4F7C-A028-690C36B5B013Q37716042-76E96489-57F8-473D-BA11-87FAD0F3FB43Q37737317-1AB930AC-EE78-4F1B-B3D7-3827CE202F18Q37962045-C22741E3-AA59-4B5A-8ED8-C7D163F69CC3Q37976121-F967F569-6947-478E-9A78-D8E22DDD59F7Q37999873-83E3CDC6-498B-4B15-97A2-81A2A368FC50Q38021422-D71B7916-7D2E-4604-B607-F22D6B2D66C7Q38029244-3CB9A93B-EB9B-4F45-BE37-C0C8D2CCB9E9Q38161392-178EF244-D74F-42A5-A23E-32A26508C70BQ38217591-F978D93B-8AE9-40A0-AFCD-16A3D9E710D7Q38218013-368D1524-CC14-4179-A270-4B2DBA019823Q38266635-8F627513-CF93-4F6E-B294-956462B1A989Q38369983-FF64BB0A-3E48-4C08-A57C-537137D620E9Q38824182-E872DD28-AA51-4CCE-A328-CDA08A6AE1E7Q38876360-7A548F89-5012-4736-9CC0-0413A70619FFQ38884998-8960C2A8-4177-48B7-A457-F1A3CCFEB03CQ38912246-396A3113-016B-42C1-B49B-80F74D79B4F0
P2860
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Recombinant human hyaluronidas ...... drug and fluid administration.
@en
type
label
Recombinant human hyaluronidas ...... drug and fluid administration.
@en
prefLabel
Recombinant human hyaluronidas ...... drug and fluid administration.
@en
P2860
P356
P1476
Recombinant human hyaluronidas ...... drug and fluid administration.
@en
P2093
Gregory I Frost
P2860
P304
P356
10.1517/17425247.4.4.427
P407
P577
2007-07-01T00:00:00Z